Imugene Narrows Half-Year Loss but Net Tangible Assets Fall

Imugene ( (AU:IMU) ) has issued an announcement.

Imugene reported a net loss attributable to members of $37.8 million for the half year ended 31 December 2025, representing a 22% reduction in losses compared with the prior corresponding period. The company recorded no revenue from ordinary activities, did not declare or pay any dividends, and saw its net tangible assets per security decline to 4.7 cents from 12.6 cents a year earlier, indicating a weaker balance sheet for investors despite no changes in its controlled entities.

Management referred investors to the accompanying review of operations, directors’ report, and financial statements for detailed explanations of the results and operational progress. The absence of dividends and lower asset backing underscores that Imugene remains in an investment and development phase, with shareholder returns currently dependent on future clinical and commercial milestones rather than near-term earnings or distributions.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is a clinical-stage biotechnology company focused on developing immunotherapies, including vaccines and other biologic treatments, primarily targeting cancer. The company operates in the life sciences sector and is listed on the Australian Securities Exchange, with shareholders closely tracking its cash position and net tangible asset backing.

Average Trading Volume: 1,369,802

Technical Sentiment Signal: Sell

Current Market Cap: A$80.38M

Learn more about IMU stock on TipRanks’ Stock Analysis page.